Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.48 |
| ▸ | RXRA | P19793 | 10/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24403238 | 1.00 | NR1H2 (0.48) | NR1H2RXRANR1H3BACE1KDM1A | |
| SCHEMBL30599282 | 1.00 | NR1H2 (0.48) | NR1H2RXRANR1H3BACE1KDM1A | |
| SCHEMBL30599281 | 1.00 | NR1H2 (0.48) | NR1H2RXRANR1H3BACE1KDM1A | |
| SCHEMBL26312430 | 0.90 | NR1H2 (0.48) | NR1H2RXRANR1H3BACE1 | |
| SCHEMBL6521416 | 0.90 | NR1H2 (0.51) | NR1H2RXRANR1H3BACE1 | |
| SCHEMBL3664778 | 0.90 | NR1H2 (0.51) | NR1H2RXRANR1H3BACE1 | |
| SCHEMBL26312431 | 0.90 | NR1H2 (0.48) | NR1H2RXRANR1H3BACE1 | |
| SCHEMBL25240372 | 0.90 | NR1H2 (0.51) | NR1H2RXRANR1H3BACE1 | |
| SCHEMBL24451647 | 0.88 | BACE1 (0.53) | NR1H2RXRANR1H3BACE1 | |
| SCHEMBL3724868 | 0.88 | BACE1 (0.53) | NR1H2RXRANR1H3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023196307-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023177854-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023009187-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | NR1H2 791/4885RXRA 4817/4885NR1H3 634/4885 |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ACE2, ACE, REN | NR1H2 461/4885RXRA 3279/4885NR1H3 499/4885 |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | NR1H2 555/4885RXRA 4810/4885NR1H3 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.